A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The overall response rates to washed microbiota ...

LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation. The recommended dose is 290 mcg for IBS-C patients and 145 mcg for CIC patients, with a 72 ...

Please provide your email address to receive an email when new articles are posted on . Once-daily linaclotide improved weekly spontaneous bowel movements from 1.16 to 3.41 during the 12-week ...

How often do you poop? Yes, this is a very TMI question, but an important one. Constipation, where you’re pooping less than three times a week, is one of the most common gastrointestinal complaints ...

(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages ...

Objective: Treatment of chronic functional constipation is difficult. Both oral and topical laxatives may fail to adequately relieve symptoms, and there is risk of adverse effects such as functional ...

The US Food and Drug Administration (FDA) has expanded the indication for linaclotide (Linzess) to children as young as age 6 years with functional constipation, making it the first approved treatment ...

There are no known causes and usually multiple factors leading to the common condition that makes stools hard and difficult to pass, according to the FDA. Linzess was approved in 2012 for adult ...